ZBiotics

+12%

est. 2Y upside i

HealthcareSeries A

ZBiotics makes genetically engineered probiotics.

Rank

#2510

Sector

Biotechnology / Consumer Health

Est. Liquidity

~3Y

Data Quality

Data: Low

Data is insufficient for a robust upside estimate (revenue and valuation missing).

Last updated: July 3, 2026

Bull (25%)+166%

Exit multiple holds at 5x due to IPO window or category leadership; projected revenue $23M yields $115M exit. Net of 20% dilution, upside ~166%.

Base (30%)+52%

Exit multiple converges to 3x, exit value $69M. Net of dilution, upside ~52%.

Bear (45%)-100%

Multiple compresses to 1.5x, exit $34.6M below $40.3M preference; common stock recovers nothing, -100% return.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

10000%

Total funding ($40.3M) equals 100% of estimated entry valuation, giving preferred a full liquidation preference overhang.

Dilution Risk

moderate

Company is profitable but may still raise growth capital; assumed 20% dilution from future rounds.

Secondary Liquidity

none

No secondary market transactions reported; equity likely illiquid.

Other — 3 roles

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on ZBiotics's data — designed to show you've done your homework.

1
“What is ZBiotics' current annual revenue and how has it grown over the past 12 months?”
2
“How does the company plan to navigate the regulatory landscape given the controversy around engineered probiotics?”
3
“What is the expected timeline to a liquidity event, and what are the company's plans for the next round of financing?”

Our model estimates +12% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.